-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Huadong Medicine announced that it signed an exclusive product commercialization agreement with multinational pharmaceutical company Takeda (Takeda Pharmaceutical), and obtained the exclusive commercialization of Takeda Pharmaceutical’s innovative product Alogliptin benzoate tablets (trade name: Nisina) in mainland China Equity
.
It is reported that after the completion of the transaction, Huadong Medicine will have the commercialization rights of Nisina in China, and Takeda Pharmaceuticals will continue to be responsible for the production and supply of Nisina
.
Public information shows that the alogliptin benzoate tablets in this transaction are dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes
.
At present, only the original research product of Alogliptin benzoate tablets is sold in the domestic market
.
It is worth noting that data shows that the diabetes market in 2020 is about 55.
6 billion yuan, of which the DPP-4 agonist market will exceed 3 billion yuan
.
Under the background that the market compound growth rate has exceeded 50% in recent years, the industry believes that the sales of Alogliptin benzoate will be very substantial in the future
.
In fact, Huadong Medicine is indeed very optimistic about the prospects of this cooperation
.
It clearly stated that this cooperation has achieved a strong alliance and a more efficient allocation of resources between the two parties, which fully demonstrates the industry's affirmation of the company's ability to commercialize diabetes in the local market
.
In the future, the imported alogliptin benzoate tablets will further enrich the company’s product pipeline in the diabetes field and form a synergistic effect with the existing key varieties in the diabetes field.
At the same time, it will further consolidate and enhance the company’s market competitiveness in the domestic diabetes specialty medication field.
.
In addition to Huadong Medicine, Xin Li Thai also announced recently that the company intends to sign an agreement with South Korea D&D PHARMATECH, INC.
to obtain the exclusive license of intellectual property rights and technical information related to D&D’s innovative drug DD01 in mainland China.
Xin Li Thai presses R&D milestone payments, the total amount does not exceed 27 million US dollars
.
It is reported that the proposed development of the innovative drug DD01 is indicated for type II diabetes, obesity, non-alcoholic steatohepatitis and other diseases
.
It is understood that based on the huge market demand for diabetes, Xinlitai has been actively focusing on the field of hypoglycemia.
At present, its compound gliptin monotherapy and combined metformin administration have completed phase III clinical enrollment, and the company also has innovative small molecules The product is under development
.
For this cooperation, Xinlitai said that it will use relevant clinical trial data to accelerate the domestic research and development process
.
After the drug is marketed, it will provide patients with more convenient and effective medication options, meet the unmet clinical needs of the diabetes field, and further enrich Xinlitai's innovative product line in the field of chronic disease medication
.
In fact, the huge market will naturally attract the attention of more and more companies
.
It is understood that many domestic pharmaceutical companies, including Hengrui Pharmaceutical, Kelun Pharmaceutical, Hua Medicine, and Guizhou Bailing, are also actively participating in the development and introduction of drugs in this field
.
For example, on June 1, Huadong Medicine issued an announcement stating that the company has announced the signing of a strategic cooperation agreement with Japanese SCOHIA PHARMA, with an advance payment of 4 million US dollars, up to 24 million US dollars of potential development, registration and commercialization milestones and grading.
The net sales commission has obtained the exclusive development, production and commercialization rights of SCOHIA PHARMA's product SCO-094 in the Asia-Pacific region (25 countries and regions except Japan) for the treatment of type 2 diabetes, obesity, and non-alcoholic Endocrine diseases such as steatohepatitis
.
On April 23, Hua Medicine also issued an announcement stating that the new drug listing application submitted by the company's innovative diabetic drug dozaglietin has been formally accepted by the China National Medical Products Administration
.
It is reported that dozaglietin has become the first glucokinase activator (GKA) diabetes treatment drug to submit a new drug marketing application worldwide, and it is expected to be the first to be marketed in China
.
Industry analysts believe that with the successive launch of domestically approved products and the continuous introduction of foreign medicines, competition among enterprises in the diabetes drug market is expected to be very fierce in the future
.
.
It is reported that after the completion of the transaction, Huadong Medicine will have the commercialization rights of Nisina in China, and Takeda Pharmaceuticals will continue to be responsible for the production and supply of Nisina
.
Public information shows that the alogliptin benzoate tablets in this transaction are dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes
.
At present, only the original research product of Alogliptin benzoate tablets is sold in the domestic market
.
It is worth noting that data shows that the diabetes market in 2020 is about 55.
6 billion yuan, of which the DPP-4 agonist market will exceed 3 billion yuan
.
Under the background that the market compound growth rate has exceeded 50% in recent years, the industry believes that the sales of Alogliptin benzoate will be very substantial in the future
.
In fact, Huadong Medicine is indeed very optimistic about the prospects of this cooperation
.
It clearly stated that this cooperation has achieved a strong alliance and a more efficient allocation of resources between the two parties, which fully demonstrates the industry's affirmation of the company's ability to commercialize diabetes in the local market
.
In the future, the imported alogliptin benzoate tablets will further enrich the company’s product pipeline in the diabetes field and form a synergistic effect with the existing key varieties in the diabetes field.
At the same time, it will further consolidate and enhance the company’s market competitiveness in the domestic diabetes specialty medication field.
.
In addition to Huadong Medicine, Xin Li Thai also announced recently that the company intends to sign an agreement with South Korea D&D PHARMATECH, INC.
to obtain the exclusive license of intellectual property rights and technical information related to D&D’s innovative drug DD01 in mainland China.
Xin Li Thai presses R&D milestone payments, the total amount does not exceed 27 million US dollars
.
It is reported that the proposed development of the innovative drug DD01 is indicated for type II diabetes, obesity, non-alcoholic steatohepatitis and other diseases
.
It is understood that based on the huge market demand for diabetes, Xinlitai has been actively focusing on the field of hypoglycemia.
At present, its compound gliptin monotherapy and combined metformin administration have completed phase III clinical enrollment, and the company also has innovative small molecules The product is under development
.
For this cooperation, Xinlitai said that it will use relevant clinical trial data to accelerate the domestic research and development process
.
After the drug is marketed, it will provide patients with more convenient and effective medication options, meet the unmet clinical needs of the diabetes field, and further enrich Xinlitai's innovative product line in the field of chronic disease medication
.
In fact, the huge market will naturally attract the attention of more and more companies
.
It is understood that many domestic pharmaceutical companies, including Hengrui Pharmaceutical, Kelun Pharmaceutical, Hua Medicine, and Guizhou Bailing, are also actively participating in the development and introduction of drugs in this field
.
For example, on June 1, Huadong Medicine issued an announcement stating that the company has announced the signing of a strategic cooperation agreement with Japanese SCOHIA PHARMA, with an advance payment of 4 million US dollars, up to 24 million US dollars of potential development, registration and commercialization milestones and grading.
The net sales commission has obtained the exclusive development, production and commercialization rights of SCOHIA PHARMA's product SCO-094 in the Asia-Pacific region (25 countries and regions except Japan) for the treatment of type 2 diabetes, obesity, and non-alcoholic Endocrine diseases such as steatohepatitis
.
On April 23, Hua Medicine also issued an announcement stating that the new drug listing application submitted by the company's innovative diabetic drug dozaglietin has been formally accepted by the China National Medical Products Administration
.
It is reported that dozaglietin has become the first glucokinase activator (GKA) diabetes treatment drug to submit a new drug marketing application worldwide, and it is expected to be the first to be marketed in China
.
Industry analysts believe that with the successive launch of domestically approved products and the continuous introduction of foreign medicines, competition among enterprises in the diabetes drug market is expected to be very fierce in the future
.
